Better coordination of device and drug review processes is crucial to the future of personalized medicine and are likely to be an important focus of upcoming user fee negotiations, says the Personalized Medicine Coalition's Amy Miller.
Better aligning diagnostic and drug review processes should be one key focus of upcoming user fee negotiations, says Amy Miller.
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.
The deadline for comments is 30 June 2025
Well over 200 European standards need harmonizing under the MDR. But only around 12% have been attended to so far.
Biomedical Alliance’s Tom Melvin is on a mission to assist the European Commission comprehend the clinical gaps during its ‘targeted evaluation’ of the EU's medtech regulations and the pivotal role the EMA could play.
Well over 200 European standards need harmonizing under the MDR. But only around 12% have been attended to so far.
The medtech industry hopes to use a 90-day pause on tariffs to negotiate a “zero for zero” exemption. However, recent public comments from President Donald Trump suggest the health care sector may still be at risk.
The architect of Germany’s hospital reform, Karl Lauterbach, will not be retained as health minister according to how the new CDU/CSU-SPD coalition government plans to spread the ministerial portfolios.
